Taiho Zipalertinib NDA Accepted by FDA for NSCLC
PRINCETON, New Jersey, USA / TOKYO, Japan / CAMBRIDGE, Massachusetts, USA, April 28, 2026 Taiho Oncology, Taiho Pharmaceutical, and...
Neurodegenerative Disease
Advertisement
VectorY Therapeutics Secures EMA and MHRA Approval for VTx-002 Trial
AMSTERDAM, Netherlands & BOSTON, Massachusetts, USA, April 28, 2026 VectorY Therapeutics has announced that it has received authorization from...
XellSmart Advances Phase 2 Parkinson’s Cell Therapy Trial
Suzhou, China | April 14, 2026 XellSmart has announced the initiation of a multicenter Phase II clinical trial evaluating...
Mabwell Advances SST001 PET Tracer to Phase I Trial
SHANGHAI, CHINA, April 14, 2026 Mabwell (688062.SH) has announced that SST001 (18F-FD4), an innovative α-synuclein-targeted PET tracer developed by...
ALS Research at Risk from Proposed FY27 Budget Cuts
ARLINGTON, Virginia, United States, April 7, 2026 The ALS Association has issued a strong statement warning that the proposed...
Advertisements
Denali Therapeutics Regains DNL593 Rights for FTD
SOUTH SAN FRANCISCO, Calif., April 3, 2026 Denali Therapeutics Inc. announced it has regained full global rights to its...
Quantum BioPharma Submits IND for Lucid-MS Trial
TORONTO, April 1, 2026 Quantum BioPharma Ltd. announced the submission of an Investigational New Drug (IND) application to the...
Trethera Expands ALS Trial with MGH for TRE-515
LOS ANGELES, March 31, 2026 Trethera Corporation has announced a strategic clinical collaboration with Massachusetts General Hospital to evaluate...
Eisai and Biogen Report Strong LEQEMBI Long-Term Adherence Data
Copenhagen, Denmark | March 23, 2026 New real-world evidence presented at the AD/PD™ 2026 conference highlights that LEQEMBI® (lecanemab-irmb)...
AL-S Pharma AP-101 Shows Survival Benefit in ALS Trial
ZURICH, Switzerland, March 19, 2026 AL-S Pharma AG announced new Phase 2 clinical data for its lead investigational therapy...
Advertisement
